Market Maker Surveillance Report. XLF, PFE, MRK, AAPL, BMY, GDX, Highest Net Buy Volume With Lowest Price Friction For Friday,
March 3, 2017 / M2 PRESSWIRE / BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Friday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Friday there were 5586 companies with "abnormal" market making, 3122 companies with positive Friction Factors and 2766 companies with negative Friction Factors. Here is a list of the top companies with the highest net buy volume on Friday and lowest price Friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. Financial Select Sector SPDR (NYSE:XLF), Pfizer Inc. (NYSE:PFE), Merck & Co Inc. (NYSE:MRK), Apple Inc. (NASDAQ:AAPL), Bristol-Myers Squibb Company (NYSE:BMY), Market Vectors Gold Miners ETF (NYSE:GDX). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
Market Maker Friction Factor is shown in the chart below:
Symbol Change Percent Buy Volume Buy %% Sell Volume Sell %% Net Volume Friction XLF $0.120 0.01% 21,051,550 36.06% 18,160,013 31.11% 2,891,537 240,961 PFE $0.010 0.00% 8,661,301 40.67% 5,143,668 24.15% 3,517,633 3,517,633 MRK $0.500 0.01% 3,825,692 39.67% 1,643,348 17.04% 2,182,344 43,647 AAPL $0.810 0.01% 8,069,131 38.42% 5,177,422 24.65% 2,891,709 35,700 BMY $0.400 0.01% 4,755,225 42.37% 2,106,182 18.77% 2,649,043 66,226 GDX $0.290 0.01% 31,686,708 34.50% 20,602,873 22.43% 11,083,835 382,201Analysis of the Friction Factor chart above shows that each of the six stocks mentioned above have high net dollar gains (Change) and very low price friction in their stocks. The Friction Factor displays how many more shares of buying than selling are required to move a stock higher by one cent or how many more shares of selling than buying moves a stock lower by 1 cent.
For example, the chart above shows XLF with a Net Buy Volume of 2,891,537 shares and a Friction Factor of 240,961 shares. That means that it takes 240,961 more shares of buying than selling to move XLF higher by one penny. This means the Market Makers are allowing the stock to move up higher as of Friday (lower friction). And with one of the highest Net Buy Volumes, the combination of low friction and high net buy volume is bullish.
Financial Select Sector SPDR (NYSE:XLF) - FINANCIAL SEL SPD.
Pfizer Inc. (NYSE:PFE) - Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. It operates through two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as dietary supplements, pain management, gastrointestinal, and respiratory and personal care. This segment offers products primarily under the Prevnar 13, Xeljanz, Eliquis, Lyrica, Enbrel, Viagra, Ibrance, Xtandi, Advil, and Centrum brands. The EH segment offers products that will lose or have lost marketing patent protection; branded generic products; sterile injectable products; biosimilars; and infusion systems. It provides products under the Lipitor, Premarin family, Norvasc, Lyrica, Celebrex, and Pristiq brand names. This segment also engages in contract manufacturing business. The company has licensing agreements with Cellectis SA and AstraZeneca plc; and collaborative agreements with Eli Lilly & Company and Merck KGaA. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as centers for disease control and prevention. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York..
Merck & Co Inc. (NYSE:MRK) - Merck & Co., Inc. provides healthcare solutions worldwide. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, male pattern hair loss, and fertility diseases. It also offers neuromuscular blocking agents; anti-bacterial products; cholesterol modifying medicines; non-sedating antihistamine; and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat brain tumors; treat melanoma and metastatic non-small-cell lung cancer; prevent diseases caused by human papillomavirus; and vaccines for measles, mumps, rubella, varicella, chickenpox, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it offers antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics and vaccines for fishes. Additionally, the company offers companion animal products, such as ointments for otitis; diabetes mellitus treatment for dogs and cats; anthelmintic products; chewable tablets to treat fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. It serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, physician distributors, veterinarians, distributors, animal producers, and managed health care providers. The company has collaboration agreements with Adaptimmune Therapeutics plc and Agenus; and a research agreement with Proteros Biostructures to develop molecule compounds for various cancer treatments. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey..
Apple Inc. (NASDAQ:AAPL) - Apple Inc. designs, manufactures, and markets mobile communication and media devices, personal computers, and portable digital music players to consumers, small and mid-sized businesses, and education, enterprise, and government customers worldwide. The company also sells related software, services, accessories, networking solutions, and third-party digital content and applications. It offers iPhone, a line of smartphones; iPad, a line of multi-purpose tablets; and Mac, a line of desktop and portable personal computers. The company also provides iLife, a consumer-oriented digital lifestyle software application suite; iWork, an integrated productivity suite that helps users create, present, and publish documents, presentations, and spreadsheets; and other application software, such as Final Cut Pro, Logic Pro X, and FileMaker Pro. In addition, it offers Apple TV that connects to consumers TV and enables them to access digital content directly for streaming high definition video, playing music and games, and viewing photos; Apple Watch, a personal electronic device; and iPod, a line of portable digital music and media players. Further, the company sells Apple-branded and third-party Mac-compatible, and iOS-compatible accessories, such as headphones, displays, storage devices, Beats products, and other connectivity and computing products and supplies. Additionally, it offers iCloud, a cloud service; AppleCare that offers support options for its customers; and Apple Pay, a mobile payment service. The company sells and delivers digital content and applications through the iTunes Store, App Store, Mac App Store, TV App Store, iBooks Store, and Apple Music. It also sells its products through its retail and online stores, and direct sales force, as well as through third-party cellular network carriers, wholesalers, retailers, and value-added resellers. Apple Inc. was founded in 1977 and is headquartered in Cupertino, California..
Bristol-Myers Squibb Company (NYSE:BMY) - Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers chemically-synthesized drug or small molecule, and biologic in various therapeutic areas, such as oncology; cardiovascular; immunoscience; and virology comprising human immunodeficiency virus infection (HIV). Its products include Empliciti, a humanized monoclonal antibody to treat multiple myeloma; Opdivo, a human monoclonal antibody to treat renal cell carcinoma, non-small cell lung cancer, classical Hodgkin lymphoma, gastric cancer, melanoma, metastatic urothelial carcinoma, and squamous cell carcinoma of the head and neck; Erbitux, an IgG1 monoclonal antibody that blocks the epidermal growth factor receptor; Sprycel, a tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; and Yervoy, a monoclonal antibody for metastatic melanoma. The company s products also comprise Eliquis, an oral factor Xa inhibitor targeted at stroke prevention in atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; Baraclude to treat chronic hepatitis B virus; Daklinza and Sunvepra to treat hepatitis C virus (HCV); Reyataz and Sustiva to treat HIV; Abilify, an antipsychotic agent for adults with schizophrenia, bipolar mania disorder, and depressive disorder; Beclabuvir, a non-nucleoside NS5B inhibitor for the treatment of HCV; and Orencia to treat rheumatoid arthritis. The company has collaboration with Portola Pharmaceuticals, Inc. to develop and commercialize andexanet alfa, an investigational agent; and license agreement with Nitto Denko Corporation to develop and commercialize siRNA molecules targeted at HSP47 in vitamin A. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York..
Market Vectors Gold Miners ETF (NYSE:GDX) - MKT VECTORS GOLD ETF.
About BUYINS.NET
BUYINS.NET, http://www.buyins.net, monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:
REGULATORY & COMPLIANCE NEWS Friction Factor - Market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements" Naked Shorts (RegSho) - Tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO
INVESTMENTS & TRADING Earnings - Predicts probability, price move and length of move before and after all US stock earnings reports Seasonality - Predicts probability, price move and length of move based on exact time of year for all US stocks Group Correlation - Tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups SqueezeTrigger - Massive database that tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock. Valuation - Tracks all known valuation models and applies them. GATS - Tracks and quantifies known trading strategies by backtesting, optimizing and running genetic algorithms and neural networks to ascertain best trading strategies. PatternScan - Automates tracking of every technical pattern and predicts next move in stocks. Insider - Tracks insiders trading records and determines trading performance. Trades by higher-level insiders are generally more predictive than trades by lower level insiders Events - Tracks patterns directly correlated to specific events.
SqueezeTrigger is a registered trademark, Reg. No. 3,120,641
DISCLAIMER:
BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. [symbol] has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.
Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net